Share Price and Basic Stock Data
Last Updated: December 15, 2025, 3:40 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ANG Lifesciences India Ltd operates within the pharmaceuticals sector, a field that has seen varied fortunes in recent years. The company’s revenue trajectory has been quite tumultuous; for instance, sales peaked at ₹348.52 Cr in FY 2022 but spiraled down to ₹206.82 Cr in FY 2023, reflecting a staggering decline of approximately 41%. This downward trend continued into FY 2024, where revenues further dipped to ₹131.30 Cr. However, the latest data for the trailing twelve months (TTM) indicates a slight recovery, with sales standing at ₹98.27 Cr. The company has faced significant challenges, including fluctuating demand and operational inefficiencies, which have considerably affected its revenue streams. The quarter-on-quarter sales figures reveal a similar pattern, with a noticeable drop in sales from ₹71.56 Cr in June 2022 to just ₹31.88 Cr in March 2023, before showing some recovery in subsequent quarters. Such volatility raises questions about the company’s strategy and market positioning.
Profitability and Efficiency Metrics
Profitability remains a critical concern for ANG Lifesciences, as evidenced by its negative net profit margins in recent years. The reported net profit for FY 2023 was a loss of ₹0.66 Cr, which worsened to a loss of ₹8.37 Cr in the TTM. This downward trend in profitability is alarming, particularly given the company’s operating profit margin (OPM), which has fluctuated significantly, from a high of 18.81% in FY 2022 to a negative OPM of -1.14% in FY 2025. The company’s efficiency metrics, such as the cash conversion cycle (CCC), have deteriorated, increasing to 158.34 days, suggesting that the company is struggling to convert its investments into cash effectively. This inefficiency can lead to liquidity issues, especially given the high level of borrowings at ₹70.58 Cr. Overall, the profitability picture is concerning, and the company must address these inefficiencies to restore investor confidence.
Balance Sheet Strength and Financial Ratios
ANG Lifesciences’ balance sheet exhibits a mixed picture. While the company has recorded reserves of ₹53.75 Cr, its borrowing levels are quite high at ₹70.58 Cr, leading to a total debt-to-equity ratio of 1.26. This indicates a leveraged position, which could pose risks if the company fails to generate sufficient cash flows to service its debt. The interest coverage ratio is alarming at -0.02x, suggesting that the company is currently unable to cover its interest obligations from operational earnings. On a positive note, the current ratio of 1.15 suggests that the company can cover its short-term liabilities, at least in the immediate term. However, the declining book value per share from ₹80.81 in FY 2022 to ₹48.99 in FY 2025 raises concerns about the company’s long-term financial health. Investors should remain cautious about the sustainability of the firm’s financial standing.
Shareholding Pattern and Investor Confidence
The shareholding structure of ANG Lifesciences reflects a significant degree of promoter control, with promoters holding 70.60% of the equity as of March 2025. This high level of promoter ownership can be a double-edged sword. On one hand, it signifies strong commitment from the founders, potentially aligning their interests with those of minority shareholders. On the other hand, it could lead to concerns about governance and transparency, particularly in light of the company’s recent financial struggles. The public shareholding stands at 29.40%, indicating a relatively stable investor base, although the number of shareholders has declined slightly to 6,273 as of March 2025. This could suggest waning interest in the stock, especially given the company’s poor financial performance. Investor confidence could be further impacted by the company’s ongoing operational challenges and the lack of substantial foreign institutional or domestic institutional investment.
Outlook, Risks, and Final Insight
The outlook for ANG Lifesciences appears fraught with challenges. The company’s declining revenues and profitability metrics indicate that it needs to reassess its operational strategies to regain market traction. Key risks include its high debt levels and negative profitability, which could limit financial flexibility and growth opportunities. Additionally, the increasing cash conversion cycle could lead to liquidity issues, making it harder for the company to navigate through challenging market conditions. Investors should consider these risks carefully, as they weigh the potential for recovery against the backdrop of a volatile pharmaceutical market. While there may be opportunities for turnaround, such as improving operational efficiencies or diversifying product lines, the current financial health raises significant red flags. A cautious approach may be warranted, as the company must demonstrate substantial improvements to restore investor confidence and secure its financial future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 237/84.3 | 32.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,234 Cr. | 391 | 479/192 | 87.7 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.4 Cr. | 31.0 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,419.39 Cr | 1,154.58 | 52.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71.56 | 58.39 | 45.17 | 31.88 | 50.61 | 29.58 | 17.10 | 34.08 | 16.18 | 32.16 | 23.91 | 17.67 | 24.53 |
| Expenses | 60.28 | 49.15 | 43.03 | 43.48 | 44.94 | 28.26 | 18.82 | 30.23 | 18.11 | 29.70 | 25.89 | 18.03 | 22.67 |
| Operating Profit | 11.28 | 9.24 | 2.14 | -11.60 | 5.67 | 1.32 | -1.72 | 3.85 | -1.93 | 2.46 | -1.98 | -0.36 | 1.86 |
| OPM % | 15.76% | 15.82% | 4.74% | -36.39% | 11.20% | 4.46% | -10.06% | 11.30% | -11.93% | 7.65% | -8.28% | -2.04% | 7.58% |
| Other Income | 0.12 | 0.20 | 0.32 | 9.20 | 0.34 | 0.33 | -0.09 | -1.49 | 1.36 | 0.36 | -0.03 | 0.75 | 0.17 |
| Interest | 3.17 | 3.20 | 2.84 | 1.11 | 1.94 | 1.96 | 1.99 | 3.44 | 1.67 | 1.87 | 1.71 | 2.05 | 1.61 |
| Depreciation | 1.88 | 1.90 | 1.92 | 2.82 | 1.94 | 1.97 | 2.02 | 1.83 | 1.51 | 1.62 | 1.84 | 1.30 | 1.45 |
| Profit before tax | 6.35 | 4.34 | -2.30 | -6.33 | 2.13 | -2.28 | -5.82 | -2.91 | -3.75 | -0.67 | -5.56 | -2.96 | -1.03 |
| Tax % | 47.24% | 39.63% | -30.43% | -20.54% | 25.35% | -10.09% | -20.96% | 23.71% | -26.13% | 61.19% | -17.99% | -34.46% | -23.30% |
| Net Profit | 3.34 | 2.62 | -1.60 | -5.03 | 1.60 | -2.05 | -4.59 | -3.60 | -2.77 | -1.07 | -4.57 | -1.94 | -0.79 |
| EPS in Rs | 2.57 | 2.02 | -1.23 | -3.85 | 1.23 | -1.57 | -3.52 | -2.76 | -2.12 | -0.82 | -3.50 | -1.49 | -0.60 |
Last Updated: August 19, 2025, 11:45 pm
Below is a detailed analysis of the quarterly data for ANG Lifesciences India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 24.53 Cr.. The value appears strong and on an upward trend. It has increased from 17.67 Cr. (Mar 2025) to 24.53 Cr., marking an increase of 6.86 Cr..
- For Expenses, as of Jun 2025, the value is 22.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.03 Cr. (Mar 2025) to 22.67 Cr., marking an increase of 4.64 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.86 Cr.. The value appears strong and on an upward trend. It has increased from -0.36 Cr. (Mar 2025) to 1.86 Cr., marking an increase of 2.22 Cr..
- For OPM %, as of Jun 2025, the value is 7.58%. The value appears strong and on an upward trend. It has increased from -2.04% (Mar 2025) to 7.58%, marking an increase of 9.62%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.75 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.58 Cr..
- For Interest, as of Jun 2025, the value is 1.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.05 Cr. (Mar 2025) to 1.61 Cr., marking a decrease of 0.44 Cr..
- For Depreciation, as of Jun 2025, the value is 1.45 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.30 Cr. (Mar 2025) to 1.45 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.03 Cr.. The value appears strong and on an upward trend. It has increased from -2.96 Cr. (Mar 2025) to -1.03 Cr., marking an increase of 1.93 Cr..
- For Tax %, as of Jun 2025, the value is -23.30%. The value appears to be increasing, which may not be favorable. It has increased from -34.46% (Mar 2025) to -23.30%, marking an increase of 11.16%.
- For Net Profit, as of Jun 2025, the value is -0.79 Cr.. The value appears strong and on an upward trend. It has increased from -1.94 Cr. (Mar 2025) to -0.79 Cr., marking an increase of 1.15 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.60. The value appears strong and on an upward trend. It has increased from -1.49 (Mar 2025) to -0.60, marking an increase of 0.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:14 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.73 | 92.08 |
| Expenses | 29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 90.75 | 90.34 |
| Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.02 | 1.74 |
| OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -1.14% | 1.89% |
| Other Income | 0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 1.99 | 1.10 |
| Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.64 | 6.96 |
| Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 6.04 |
| Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -10.16 |
| Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
| Net Profit | 0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -8.10 |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -6.20 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.61% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 110.53% | 312.50% | 70.91% | 31.91% | 51.88% | 7.96% | 18.85% | 447.72% | -101.66% | -1210.61% | -19.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 201.97% | -241.59% | -38.99% | 19.97% | -43.92% | 10.89% | 428.87% | -549.39% | -1108.94% | 1191.07% |
ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -45% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 10, 2025, 3:48 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.68 | 3.68 | 3.68 | 3.68 | 5.18 | 5.18 | 5.18 | 5.18 | 10.37 | 13.06 | 13.06 | 13.06 | 13.06 |
| Reserves | -0.97 | -0.57 | 1.09 | 3.81 | 17.99 | 23.58 | 29.37 | 36.17 | 73.11 | 72.48 | 64.01 | 53.75 | 52.20 |
| Borrowings | 11.03 | 10.15 | 11.77 | 14.01 | 17.42 | 21.90 | 20.83 | 42.40 | 60.99 | 55.56 | 59.36 | 70.58 | 78.12 |
| Other Liabilities | 11.44 | 12.59 | 18.95 | 25.34 | 27.57 | 30.24 | 38.69 | 58.49 | 124.21 | 111.40 | 81.00 | 71.28 | 80.68 |
| Total Liabilities | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 | 224.06 |
| Fixed Assets | 9.04 | 8.78 | 9.02 | 8.90 | 9.47 | 20.60 | 20.94 | 21.89 | 82.32 | 78.68 | 53.35 | 52.63 | 49.79 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.07 | 11.57 | 0.16 | 0.23 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 |
| Other Assets | 16.12 | 17.05 | 26.45 | 37.85 | 47.10 | 60.12 | 72.88 | 119.93 | 182.84 | 170.30 | 160.56 | 152.52 | 170.75 |
| Total Assets | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 | 224.06 |
Below is a detailed analysis of the balance sheet data for ANG Lifesciences India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.06 Cr..
- For Reserves, as of Sep 2025, the value is 52.20 Cr.. The value appears to be declining and may need further review. It has decreased from 53.75 Cr. (Mar 2025) to 52.20 Cr., marking a decrease of 1.55 Cr..
- For Borrowings, as of Sep 2025, the value is 78.12 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 70.58 Cr. (Mar 2025) to 78.12 Cr., marking an increase of 7.54 Cr..
- For Other Liabilities, as of Sep 2025, the value is 80.68 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 71.28 Cr. (Mar 2025) to 80.68 Cr., marking an increase of 9.40 Cr..
- For Total Liabilities, as of Sep 2025, the value is 224.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 208.67 Cr. (Mar 2025) to 224.06 Cr., marking an increase of 15.39 Cr..
- For Fixed Assets, as of Sep 2025, the value is 49.79 Cr.. The value appears to be declining and may need further review. It has decreased from 52.63 Cr. (Mar 2025) to 49.79 Cr., marking a decrease of 2.84 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 3.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.52 Cr..
- For Other Assets, as of Sep 2025, the value is 170.75 Cr.. The value appears strong and on an upward trend. It has increased from 152.52 Cr. (Mar 2025) to 170.75 Cr., marking an increase of 18.23 Cr..
- For Total Assets, as of Sep 2025, the value is 224.06 Cr.. The value appears strong and on an upward trend. It has increased from 208.67 Cr. (Mar 2025) to 224.06 Cr., marking an increase of 15.39 Cr..
However, the Borrowings (78.12 Cr.) are higher than the Reserves (52.20 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.14 | -7.03 | -7.04 | -7.51 | -10.12 | -10.26 | -8.40 | -27.07 | 4.55 | -43.89 | -49.81 | -71.60 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 264.24 |
| Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
| Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
| Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 158.34 |
| Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 27.88 | 74.97 | 71.80 |
| ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -3.54% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.39 |
| Diluted EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.09 |
| Cash EPS (Rs.) | -4.33 | -1.36 | 6.96 | 44.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Revenue From Operations / Share (Rs.) | 71.10 | 111.89 | 168.39 | 341.77 |
| PBDIT / Share (Rs.) | -0.18 | 7.92 | 18.27 | 65.87 |
| PBIT / Share (Rs.) | -5.37 | 1.51 | 11.11 | 60.20 |
| PBT / Share (Rs.) | -12.03 | -8.20 | 2.01 | 51.61 |
| Net Profit / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| NP After MI And SOA / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| PBDIT Margin (%) | -0.26 | 7.07 | 10.84 | 19.27 |
| PBIT Margin (%) | -7.54 | 1.34 | 6.59 | 17.61 |
| PBT Margin (%) | -16.91 | -7.33 | 1.19 | 15.10 |
| Net Profit Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| NP After MI And SOA Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| Return on Networth / Equity (%) | -19.40 | -13.29 | -0.30 | 48.12 |
| Return on Capital Employeed (%) | -8.13 | 2.01 | 12.35 | 50.02 |
| Return On Assets (%) | -5.40 | -4.18 | -0.09 | 13.85 |
| Long Term Debt / Equity (X) | 0.29 | 0.18 | 0.23 | 0.25 |
| Total Debt / Equity (X) | 1.26 | 0.90 | 0.81 | 0.91 |
| Asset Turnover Ratio (%) | 0.39 | 0.55 | 0.77 | 0.00 |
| Current Ratio (X) | 1.15 | 1.24 | 1.15 | 1.16 |
| Quick Ratio (X) | 0.77 | 0.90 | 0.85 | 0.93 |
| Inventory Turnover Ratio (X) | 1.82 | 2.14 | 3.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 2.57 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 2.24 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.43 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.76 |
| Interest Coverage Ratio (X) | -0.02 | 0.94 | 2.01 | 7.67 |
| Interest Coverage Ratio (Post Tax) (X) | -0.42 | 0.23 | 0.97 | 5.53 |
| Enterprise Value (Cr.) | 106.47 | 122.38 | 163.11 | 313.54 |
| EV / Net Operating Revenue (X) | 1.15 | 0.83 | 0.74 | 0.88 |
| EV / EBITDA (X) | -429.30 | 11.83 | 6.84 | 4.59 |
| MarketCap / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 97.42 |
| Price / BV (X) | 0.46 | 0.77 | 1.15 | 2.90 |
| Price / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| EarningsYield | -0.41 | -0.17 | 0.00 | 0.16 |
After reviewing the key financial ratios for ANG Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.33. This value is below the healthy minimum of 3. It has decreased from -1.36 (Mar 24) to -4.33, marking a decrease of 2.97.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.10. It has decreased from 111.89 (Mar 24) to 71.10, marking a decrease of 40.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.18. This value is below the healthy minimum of 2. It has decreased from 7.92 (Mar 24) to -0.18, marking a decrease of 8.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.37. This value is below the healthy minimum of 0. It has decreased from 1.51 (Mar 24) to -5.37, marking a decrease of 6.88.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.03. This value is below the healthy minimum of 0. It has decreased from -8.20 (Mar 24) to -12.03, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For PBDIT Margin (%), as of Mar 25, the value is -0.26. This value is below the healthy minimum of 10. It has decreased from 7.07 (Mar 24) to -0.26, marking a decrease of 7.33.
- For PBIT Margin (%), as of Mar 25, the value is -7.54. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -7.54, marking a decrease of 8.88.
- For PBT Margin (%), as of Mar 25, the value is -16.91. This value is below the healthy minimum of 10. It has decreased from -7.33 (Mar 24) to -16.91, marking a decrease of 9.58.
- For Net Profit Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 5. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 8. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is -19.40. This value is below the healthy minimum of 15. It has decreased from -13.29 (Mar 24) to -19.40, marking a decrease of 6.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -8.13. This value is below the healthy minimum of 10. It has decreased from 2.01 (Mar 24) to -8.13, marking a decrease of 10.14.
- For Return On Assets (%), as of Mar 25, the value is -5.40. This value is below the healthy minimum of 5. It has decreased from -4.18 (Mar 24) to -5.40, marking a decrease of 1.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.26. This value exceeds the healthy maximum of 1. It has increased from 0.90 (Mar 24) to 1.26, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.55 (Mar 24) to 0.39, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1.15. This value is below the healthy minimum of 1.5. It has decreased from 1.24 (Mar 24) to 1.15, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.77, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 4. It has decreased from 2.14 (Mar 24) to 1.82, marking a decrease of 0.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 3. It has decreased from 0.94 (Mar 24) to -0.02, marking a decrease of 0.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.42. This value is below the healthy minimum of 3. It has decreased from 0.23 (Mar 24) to -0.42, marking a decrease of 0.65.
- For Enterprise Value (Cr.), as of Mar 25, the value is 106.47. It has decreased from 122.38 (Mar 24) to 106.47, marking a decrease of 15.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has increased from 0.83 (Mar 24) to 1.15, marking an increase of 0.32.
- For EV / EBITDA (X), as of Mar 25, the value is -429.30. This value is below the healthy minimum of 5. It has decreased from 11.83 (Mar 24) to -429.30, marking a decrease of 441.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.77 (Mar 24) to 0.46, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.41. This value is below the healthy minimum of 5. It has decreased from -0.17 (Mar 24) to -0.41, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ANG Lifesciences India Ltd:
- Net Profit Margin: -13.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -8.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.4% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -13.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Darbara Complex, Amritsar Punjab 143001 | cs@anglifesciences.com http://www.anglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Gupta | Managing Director |
| Mrs. Saruchi Gupta | Whole Time Director |
| Mr. Rohit Mittal | Non Executive Director |
| Mrs. Chetna | Independent Director |
| Mr. Harvinder Singh | Independent Director |
| Mr. Sukhpal Singh | Independent Director |
FAQ
What is the intrinsic value of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd's intrinsic value (as of 15 December 2025) is 84.46 which is 163.94% higher the current market price of 32.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 41.8 Cr. market cap, FY2025-2026 high/low of 49.7/21.0, reserves of ₹52.20 Cr, and liabilities of 224.06 Cr.
What is the Market Cap of ANG Lifesciences India Ltd?
The Market Cap of ANG Lifesciences India Ltd is 41.8 Cr..
What is the current Stock Price of ANG Lifesciences India Ltd as on 15 December 2025?
The current stock price of ANG Lifesciences India Ltd as on 15 December 2025 is 32.0.
What is the High / Low of ANG Lifesciences India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ANG Lifesciences India Ltd stocks is 49.7/21.0.
What is the Stock P/E of ANG Lifesciences India Ltd?
The Stock P/E of ANG Lifesciences India Ltd is .
What is the Book Value of ANG Lifesciences India Ltd?
The Book Value of ANG Lifesciences India Ltd is 50.0.
What is the Dividend Yield of ANG Lifesciences India Ltd?
The Dividend Yield of ANG Lifesciences India Ltd is 0.00 %.
What is the ROCE of ANG Lifesciences India Ltd?
The ROCE of ANG Lifesciences India Ltd is 3.54 %.
What is the ROE of ANG Lifesciences India Ltd?
The ROE of ANG Lifesciences India Ltd is 13.8 %.
What is the Face Value of ANG Lifesciences India Ltd?
The Face Value of ANG Lifesciences India Ltd is 10.0.